JOINT EVALUATION Sample Clauses

JOINT EVALUATION. Clause 21.01 Provisions, which form the basis of the Joint Job Evaluation Plan, are contained in the Collective Agreement and Job Evaluation Manual. The Job Evaluation Manual shall form an integral part of the Collective Agreement. Clause 21.02 The Plan covers all jobs falling under the scope of the Collective Agreement, in the O.C.T. Unit, Schedule "A". Clause 21.03 The parties further agree that no employee shall have their wages reduced because of the implementation of the Joint Job Evaluation Plan. Clause 21.04 The Employer shall supply a copy of the Joint Job Evaluation Manual to a probationary employee upon hiring. Clause 21.05 All jobs processed under the Joint Job Evaluation Plan shall be designated a Salary Group in the Salary Schedule "A", O.C.T. Unit, issued in conjunction with the Collective Agreement. Clause 21.06 In order to alleviate the special out-of-schedule rates, the following procedures shall apply:
Sample 1Sample 2Sample 3See All (24)
AutoNDA by SimpleDocs
JOINT EVALUATION. After 3 years of implementation a joint evaluation based on OECD standard criteria should take place in order to analyze the results of the Partnership.
Sample 1Sample 2
JOINT EVALUATION. Instrument Training
Sample 1
JOINT EVALUATION clause 21.01 provisions, which form the basis of the Joint Job evaluation plan, are contained in the collective Agreement and Job evaluation manual. The Job evaluation manual shall form an integral part of the collective Agreement.
Sample 1
JOINT EVALUATION. In the event that mice of Section 1(A)(2) are established, Lexicon shall: (i) evaluate and analyze the mice; (ii) provide Arena with a sufficient number of such mice, including an approximate equal number of male(s) and an approximate number of female(s) as maintained by Lexicon, if and when each gender is represented (but not more than 50% of the total mice established shall be provided to Arena) for Arena's evaluation and analysis; and (iii) conduct mutually-agreed to in vivo analysis of the In Vivo Compounds - Feasibility using such mice. The Parties shall jointly work together and share the results of their respective evaluations with each other. The objective of such evaluations and analyses shall be to determine the effect(s), if any, of the inclusion of the CART Technology Known GPCR receptor and/or the inclusion of the CART Technology Orphan GPCR receptor and/or the exclusion of the corresponding Known and Orphan GPCR mouse receptors, on the resulting mice. Each Party agrees to utilize reasonable efforts within a reasonable time frame to complete its evaluation and analysis, but in no event shall the respective evaluation and analysis exceed twelve (12) months from the birth of any gene-targeted mice of Section 1(A)(2). The Parties shall thereafter jointly discuss the results of the evaluations and analysis and determine, in good faith, whether to proceed to the Alliance Component of Section 1(B); to terminate the collaboration; or to jointly modify the collaboration. In the event that the Parties jointly decide to terminate the collaboration, the obligations of each Party of Section 1(A)(4)(ii) shall continue for a period of five (5) years from the date of such termination. The Parties agree to establish, in good faith, mutually acceptable criteria for the biological analyses to be conducted on the mice within ninety (90) days after the Effective Date, and to attach such criteria to the Final Agreement in the form of an appendix.
Sample 1
JOINT EVALUATION. In the event that Alliance mice of Section 1(B)(2) are established, Lexicon shall: (i) evaluate and analyze the mice; (ii) provide Arena with a sufficient number of such mice, including an approximate equal number of male(s) and an approximate number of female(s) as maintained by Lexicon, if and when each gender is represented (but not more than 50% of the total mice established shall be provided to Arena) for Arena's evaluation and analysis; and (iii) conduct mutually-agreed to in vivo analysis of the In Vivo Compounds - Alliance using such mice.. The Parties shall jointly work together and share the results of their respective evaluations with each other. The objective of such evaluations and analyses shall be to determine the effect(s), if any, of the CART Technology Alliance GPCR(s) on the resulting mice. Each Party agrees to utilize reasonable efforts within a reasonable time frame to complete its evaluation and analysis, but in no event shall the respective evaluation and analysis exceed twelve (12) months from the birth of any mice of Section 1(B)(2). The Parties, via the Steering Committee, shall thereafter jointly discuss the results of the evaluations and analysis and determine, in good faith, the ability to proceed to the Licensing Component of Section 2. The Parties agree to utilize the criteria for the biological analyses of Section 1(A)(3) for such.
Sample 1
JOINT EVALUATION. SulphCo and PC1 will jointly evaluate the PCI Report and determine their interest to further cooperate in the implementation of those findings of the PCI Report that will be accepted by SulphCo (such future cooperation, if applicable, being hereafter referred to as the "Cooperation").
Sample 1
AutoNDA by SimpleDocs
JOINT EVALUATION 
Sample 1

Related to JOINT EVALUATION

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Evaluation 1. The purposes of evaluation provisions include providing employees with feedback, and employers and employees with the opportunity and responsibility to address concerns. Where a grievance proceeds to arbitration, the arbitrator must consider these purposes, and may relieve on just and reasonable terms against breaches of time limits or other procedural requirements.

Time is Money Join Law Insider Premium to draft better contracts faster.